Tagraxofusp Clinical Trials

6 actively recruiting trials across 4 locations

No change since August 2026

Also known as: CD123-directed cytotoxin, ELZONRIS, Elzonris, SL-401, SL-701, Elzonris +1 more

Pipeline

Phase 1: 1Phase 2: 2Phase 1/2: 2

Top Sponsors

Therapeutic Advances in Childhood Leukemia Consortium1
Stemline Therapeutics, Inc.1
Stanford University1
Joshua Zeidner1
Jacqueline Garcia, MD1

Indications

Cancer6
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)2
Blood Cancers1
Relapsed Acute Myeloid Leukemia1
Lymphoma, B-Cell1

Other2 trials

A Registry-study of ELZONRIS in Participants With BPDCN

Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

Phase 2

Los Angeles, California1 trial

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Children's Hospital Los Angeles

Phase 1

Palo Alto, California1 trial

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Stanford University

Phase 1/2

Miami, Florida1 trial

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

University of Miami

Phase 2

Boston, Massachusetts1 trial

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Brigham and Women's Hospital

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.